Skip to main content
eScholarship
Open Access Publications from the University of California

NELL-1 Injection Maintains Long Bone Quantity and Quality in Ovariectomy-Induced Osteoporotic Senile Rat Model

  • Author(s): KWAK, JIN HEE
  • Advisor(s): Ting, Kang
  • et al.
Abstract

Over 10 million Americans have osteoporosis, and is the predominant cause of fractures in the elderly. Treatment of fractures in the setting of osteoporosis is complicated by a suboptimal bone regenerative response due to a decline in the number of osteoblasts, their function and survival. Consequently, an osteogenic therapeutic to prevent and treat fractures in osteoporotic patients is needed. NELL-1 (Nel-like molecule-1), a novel osteoinductive growth factor, has been shown to promote bone regeneration. In this study, we aim to demonstrate the capacity of recombinant NELL-1 to prevent ovariectomy (OVX)-induced osteoporosis in a senile rat model. Ten month old female Sprague Dawley rats underwent either sham surgery or OVX. Subsequently, 50 uL of 600 ug/ml NELL-1 lyophilized onto 0-50 um tricalcium phosphate (TCP) carrier was injected into the femoral bone marrow cavity while phosphate buffered saline (PBS) control was injected into the contralateral femur. Our microCT results showed that OVX+PBS/TCP control femurs showed a continuous decrease in bone volume (BV) and bone mineral density (BMD) from 2 to 8 weeks post-OVX. In contrast, OVX+NELL-1/TCP femurs showed resistance to OVX-induced bone resorption showing BV and BMD levels similar to that of SHAM femurs at 8 weeks post-OVX. Histology showed increased endosteal woven bone, as well as decreased adipocytes in the bone marrow of NELL-1 treated femurs compared to control. NELL-1 treated femurs also showed increased immunostaining for bone differentiation markers Osteopontin (OPN) and Osteocalcin (OCN). These findings were validated in vitro, in which overexpression of NELL-1 in OVX bone marrow stem cells resulted in increased osteogenic differentiation. Thus, NELL-1 effectively enhances in situ osteogenesis in the bone marrow, making it potentially useful in the prevention and treatment of osteoporotic fractures.

Main Content
Current View